Inhaled corticosteroids for asthma: Are they all the same?

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 1, 2009, Pages 1-12

  Baptist, A P ^a   Reddy, R C ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Candidiasis; Ciclesonide; Dysphonia; Fluticasone; Glucocorticoid; Inhalers

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE; GLUCOCORTICOID RECEPTOR; MOMETASONE FUROATE; PLASMA PROTEIN; PREDNISONE; PRODRUG; TRIAMCINOLONE;

ASTHMA; BONE DENSITY; BRONCHOSPASM; CATARACT; COLLAGEN SYNTHESIS; CORTICOSTEROID THERAPY; COUGHING; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DYSPHONIA; ECCHYMOSIS; FIRST PASS EFFECT; GLAUCOMA; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAOCULAR HYPERTENSION; MYOPATHY; REVIEW; SIDE EFFECT; SUBCAPSULAR CATARACT; THRUSH; WOUND HEALING IMPAIRMENT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; HUMANS; NEBULIZERS AND VAPORIZERS;

EID: 58149291705     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00970.x     Document Type: Review

References (84)

1. Crompton G (2006) A brief history of inhaled asthma therapy over the last fifty years. Primary Care Respiratory Journal, 15, 326 331.
2. Cameron SJ, Cooper EJ, Crompton GK, Hoare MV, Grant IW (1973) Substitution of beclomethasone aerosol for oral prednisolone in the treatment of chronic asthma. British Medical Journal, 4, 205 207.
3. Hodson ME, Batten JC, Clarke SW, Gregg I (1974) Beclomethasone dipropionate aerosol in asthma. Transfer of steroid-dependent asthmatic patients from oral prednisone to beclomethasone dipropionate aerosol. The American Review of Respiratory Disease, 110, 403 408.
4. Vilsvik JS, Schaanning J (1974) Beclomethasone dipropionate aerosol in adult steroid-dependent obstructive lung disease. Scandinavian Journal of Respiratory Disease, 55, 169 175.
5. National Heart Lung and Blood Institute (2007) Guidelines for the diagnosis and management of asthma. Bethesda, MD : National Institutes of Health, US Department of Health and Human Services.
6. Adcock IM, Ito K (2004) Steroid resistance in asthma: a major problem requiring novel solutions or a non-issue? Current Opinion in Pharmacology, 4, 257 262.
7. Barnes PJ (2006) Corticosteroids: the drugs to beat. European Journal of Pharmacology, 533, 2 14.
8. Chanez P, Wenzel SE, Anderson GP et al. (2007) Severe asthma in adults: what are the important questions? Journal of Allergy and Clinical Immunology, 119, 1337 1348.
9. Leach CL, Davidson PJ, Boudreau RJ (1998) Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. European Respiratory Journal, 12, 1346 1353.
10. Willey RF, Milne LJ, Crompton GK, Grant IW (1976) Beclomethasone dipropionate aerosol and oropharyngeal candidiasis. British Journal of Diseases of the Chest, 70, 32 38.
11. Kennedy WA, Laurier C, Gautrin D et al. (2000) Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids. Journal of Clinical Epidemiology, 53, 696 701.
12. Roland NJ, Bhalla RK, Earis J (2004) The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest, 126, 213 219.
13. Buhl R (2006) Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy, 61, 518 526.
14. Selroos O, Backman R, Forsen KO et al. (1994) Local side-effects during 4-year treatment with inhaled corticosteroids - a comparison between pressurized metered-dose inhalers and Turbuhaler. Allergy, 49, 888 890.
15. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK (1995) Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. European Respiratory Journal, 8, 590 592.
16. Dubus J-C, Mely L, Huiart L, Marguet C, Le Roux P (2003) Cough after inhalation of corticosteroids delivered from spacer devices in children with asthma. Fundamental and Clinical Pharmacology, 17, 627 631.
17. Lipworth BJ (1999) Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Archives of Internal Medicine, 159, 941 955.
18. Weiner P, Berar-Yanay N, Davidovich A, Magadle R (1999) Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest, 116, 931 934.
19. Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A (1994) An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. British Journal of Clinical Pharmacology, 38, 521 525.
20. White M, Crisalida T, Li H, Economides A, Kaliner M (2006) Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma. Annals of Allergy, Asthma, and Immunology, 96, 437 444.
21. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D (2002) Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Archives of Disease in Childhood, 87, 457 461.
22. Autio P, Karjalainen J, Risteli L, Risteli J, Kiistala U, Oikarinen A (1996) Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. American Journal of Respiratory and Critical Care Medicine, 153, 1172 1175.
23. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY (1990) Purpura and dermal thinning associated with high dose inhaled corticosteroids. British Medical Journal, 300, 1548 1551.
24. Tashkin DP, Murray HE, Skeans M, Murray RP (2004) Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. Chest, 126, 1123 1133.
25. Mak VH, Melchor R, Spiro SG (1992) Easy bruising as a side-effect of inhaled corticosteroids. European Respiratory Journal, 5, 1068 1074.
26. Pauwels RA, Lofdahl CG, Laitinen LA et al. (1999) Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 340, 1948 1953.
27. Roy A, Leblanc C, Paquette L et al. (1996) Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function. European Respiratory Journal, 9, 226 231.
28. Egan JJ, Maden C, Kalra S, Adams JE, Eastell R, Woodcock AA (1999) A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. European Respiratory Journal, 13, 1267 1275.
29. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S (1995) Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 96, 571 579.
30. Herrala J, Puolijoki H, Impivaara O, Liippo K, Tala E, Nieminen MM (1994) Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate. Bone, 15, 621 623.
31. Marystone JF, Barrett-Connor EL, Morton DJ (1995) Inhaled and oral corticosteroids: their effects on bone mineral density in older adults. American Journal of Public Health, 85, 1693 1695.
32. Kerstjens HA, Postma DS, van Doormaal JJ et al. (1994) Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group. Thorax, 49, 652 656.
33. Pouw EM, Prummel MF, Oosting H, Roos CM, Endert E (1991) Beclomethasone inhalation decreases serum osteocalcin concentrations. British Medical Journal, 302, 627 628.
34. Teelucksingh S, Padfield PL, Tibi L, Gough KJ, Holt PR (1991) Inhaled corticosteroids, bone formation, and osteocalcin. Lancet, 338, 60 61.
35. Wong CA, Walsh LJ, Smith CJP et al. (2000) Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet, 355, 1399 1403.
36. Kelly HW, Nelson HS (2003) Potential adverse effects of the inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 112, 469 478 (quiz 79).
37. Rossi GA, Cerasoli F, Cazzola M (2007) Safety of inhaled corticosteroids: room for improvement. Pulmonary Pharmacology & Therapeutics, 20, 23 35.
38. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K (2004) Safety of inhaled corticosteroids. Proceedings of the American Thoracic Society, 1, 171 175.
39. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G (2002) Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane database of systematic reviews (Online), CD003537.
40. Toogood JH, Markov AE, Baskerville J, Dyson C (1993) Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. Journal of Allergy and Clinical Immunology, 91, 571 579.
41. Cumming RG, Mitchell P, Leeder SR (1997) Use of inhaled corticosteroids and the risk of cataracts. New England Journal of Medicine, 337, 8 14.
42. Smeeth L, Boulis M, Hubbard R, Fletcher AE (2003) A population based case-control study of cataract and inhaled corticosteroids. British Journal of Ophthalmology, 87, 1247 1251.
43. Uboweja A, Malhotra S, Pandhi P (2006) Effect of inhaled corticosteroids on risk of development of cataract: a meta-analysis. Fundamental and Clinical Pharmacology, 20, 305 309.
44. Garbe E, LeLorier J, Boivin JF, Suissa S (1997) Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA, 277, 722 727.
45. Samiy N, Walton DS, Dreyer EB (1996) Inhaled steroids: effect on intraocular pressure in patients without glaucoma. Canadian Journal of Ophthalmology, 31, 120 123.
46. Sin DD, Tu JV (2001) Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. European Respiratory Journal, 17, 380 385.
47. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R (1982) Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. European Journal of Respiratory Diseases. Supplement, 122, 86 95.
48. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N (2001) Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. British Journal of Clinical Pharmacology, 51, 400 409.
49. Derendorf H (2007) Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. Journal of Clinical Pharmacology, 47, 782 789.
50. Thorsson L, Dahlström K, Edsbäcker S, Kallén A, Paulson J, Wirén JE (1997) Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. British Journal of Clinical Pharmacology, 43, 155 161.
51. Nave R, Bethke TD, van Marle SP, Zech K (2004) Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clinical Pharmacokinetics, 43, 479 486.
52. Hübner M, Hochhaus G, Derendorf H (2005) Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunology and allergy clinics of North America, 25, 469 488.
53. Tunek A, Sjodin K, Hallstrom G (1997) Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metabolism and Disposition, 25, 1311 1317.
54. Hubbard WC, Blum AE, Bickel CA, Heller NM, Schleimer RP (2003) Detection and quantitation of fatty acid acyl conjugates of triamcinolone acetonide via gas chromatography-electron-capture negative-ion mass spectrometry. Analytical Biochemistry, 322, 243 250.
55. Nave R, Meyer W, Fuhst R, Zech K (2005) Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulmonary Pharmacology & Therapeutics, 18, 390 396.
56. Mutch E, Nave R, McCracken N, Zech K, Williams FM (2007) The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochemical Pharmacology, 73, 1657 1664.
57. Rohatagi S, Arya V, Zech K et al. (2003) Population pharmacokinetics and pharmacodynamics of ciclesonide. Journal of Clinical Pharmacology, 43, 365 378.
58. Adams N, Bestall J, Jones PW (2001) Budesonide at different doses for chronic asthma. Cochrane database of systematic reviews (Online), CD003271.
59. Adams NP, Jones PW (2006) The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respiratory Medicine, 100, 1297 1306.
60. Bateman E, Karpel J, Casale T, Wenzel S, Banerji D (2006) Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest, 129, 1176 1187.
61. Meltzer EO, Wenzel S (2006) The efficacy and safety of mometasone furoate delivered via a dry powder inhaler for the treatment of asthma. Journal of Asthma, 43, 765 772.
62. Fish JE, Karpel JP, Craig TJ et al. (2000) Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. Journal of Allergy and Clinical Immunology, 106, 852 860.
63. Larsen JS, Hahn M, Ekholm B, Wick KA (1994) Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. Journal of Asthma, 31, 193 199.
64. Guidry GG, Brown WD, Stogner SW, George RB (1992) Incorrect use of metered dose inhalers by medical personnel. Chest, 101, 31 33.
65. Thorsson L, Geller D (2005) Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide. Respiratory Medicine, 99, 836 849.
66. Cates CJ, Bestall J, Adams N (2006) Holding chambers versus nebulisers for inhaled steroids in chronic asthma. Cochrane database of systematic reviews (Online), CD001491.
67. Dolovich MB (2002) Aeorsol delivery devices and airways/lung deposition. In : Schleimer RP, O'Byrne PM, Szefler SJ, Brattsand R, eds. Aeorsol delivery devices and airways/lung deposition. Basel : Marcel Dekker, 169 212.
68. Olsson B (1995) Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers? Journal of Aerosol Medicine, 8 (Suppl. 3 S13 S18 (discussion S19).
69. Borgström L, Asking L, Thorsson L (2005) Idealhalers or realhalers? A comparison of Diskus and Turbuhaler. International Journal of Clinical Practice, 59, 1488 1495.
70. Thomas M, Williams AE (2005) Are outcomes the same with all dry powder inhalers? International Journal of Clinical Practice, 59 (Suppl 149 33 35.
71. Frew AJ, Langley SJ, Perrin V, Hertog MG (2002) Effects of 4-week treatment with low-dose budesonide (100 micrograms BID) from a novel inhaler Airmax and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma. Respiratory Medicine, 96, 542 547.
72. Dahlström K, Thorsson L, Larsson P, Nikander K (2003) Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Annals of Allergy, Asthma, and Immunology, 90, 226 232.
73. Thorsson L, Edsbacker S, Conradson TB (1994) Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. European Respiratory Journal, 7, 1839 1844.
74. Dolovich MB, Ahrens RC, Hess DR et al. (2005) Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest, 127, 335 371.
75. Bodor N, Buchwald P (2006) Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Current Pharmaceutical Design, 12, 3241 3260.
76. Biggadike K, Uings I, Farrow SN (2004) Designing corticosteroid drugs for pulmonary selectivity. Proceedings of the American Thoracic Society, 1, 352 355.
77. Dickens GR, Wermeling DP, Matheny CJ et al. (2000) Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. Annals of Allergy, Asthma, and Immunology, 84, 528 532.
78. Mollmann H, Wagner M, Krishnaswami S et al. (2001) Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. Journal of Clinical Pharmacology, 41, 1329 1338.
79. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W (2006) Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. European Respiratory Journal, 28, 1042 1050.
80. Crim C, Pierre LN, Daley-Yates PT (2001) A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clinical Therapeutics, 23, 1339 1354.
81. Tayab ZR, Fardon TC, Lee DKC et al. (2007) Pharmacokinetic/ pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. British Journal of Clinical Pharmacology, 64, 698 705.
82. Valotis A, Neukam K, Elert O, Högger P (2004) Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. Journal of Pharmaceutical Sciences, 93, 1337 1350.
83. Belvisi MG, Bundschuh DS, Stoeck M et al. (2005) Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. Journal of Pharmacology and Experimental Therapeutics, 314, 568 574.
84. Jaffuel D, Demoly P, Gougat C et al. (2000) Transcriptional potencies of inhaled glucocorticoids. American Journal of Respiratory and Critical Care Medicine, 162, 57 63.